Protagonist Therapeutics stock fell 1.38 percent on October 6

Published on 10/07/2026 at 01:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Protagonist Therapeutics stock drew a Strong Buy consensus with a USD 174.69 target on October 6. Second quarter revenue reached USD 213.47 million and diluted EPS hit USD 2.29.

PTGX, US74366E1029, Illustration mit AI erstellt.

Protagonist Therapeutics (ISIN US74366E1029) was last at USD 138.69 on Nasdaq on October 6, 2026, at 4:00 p.m. ET, down 1.38 percent from USD 140.63. The key valuation signal is the analyst consensus, which places the average target well above the latest quote.

Consensus target sits above the quote

According to Investing.com on October 6, 2026, 13 analysts rated Protagonist Therapeutics Strong Buy and set an average 12-month price target of USD 174.69. The same consensus showed a high target of USD 225 and a low target of USD 149, putting the average target 25.96 percent above the USD 138.69 Nasdaq quote.

The spread matters because the stock remained USD 22.12 below the 52-week high of USD 160.81 on October 6, while the 52-week low stood at USD 62.24. The current price is therefore closer to the yearly high than to the yearly low, but the daily move still pointed lower.

Second quarter earnings reset the base

MarketBeat reported on October 2, 2026, that Protagonist delivered diluted EPS of USD 2.29 for the second quarter of 2026, versus a USD 2.27 consensus estimate. Revenue reached USD 213.47 million against a USD 212.03 million estimate and increased 3,746.8 percent year over year.

The combination of a small EPS beat and a USD 1.44 million revenue beat gives the current target debate a concrete operating reference. It also separates the latest market price from the most recent earnings comparison, because the second quarter ended June 30, 2026, while the quote above reflects October trading.

November results provide the next checkpoint

Investing.com lists November 5, 2026, as Protagonist Therapeutics' next earnings date. That report will test whether the revenue scale reached in the second quarter can support the USD 174.69 consensus target while the stock trades below its yearly high.

PTGX stock stays below its yearly high

Protagonist Therapeutics was last at USD 138.69 on Nasdaq on October 6, 2026, at 4:00 p.m. ET, with a daily change of minus 1.38 percent and a market capitalization of USD 8.9 billion.